| http://www.w3.org/ns/prov#value | - Seeing Green: Expanding off-label use of Genentech???s Avastin rather than the company???s more expensive Lucentis to treat a certain type of macular degeneration could save Medicare $500 million per year, according to an unpublished study reviewed by the WSJ. Avastin, approved for use against some forms of cancer, costs $42 a dose when used for the eye condition while Lucentis, FDA-approved for w
|
